6 results
Pain Assessment and Management Initiative (PAMI) - Non-Opioid Analgesics - Agents and Dosing

#Management #Pain #Pharmacology #NonOpioid
Pain Assessment ... - Agents and Dosing ... #Management #Pain ... #Pharmacology # ... #Table #PAMI
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
GLP-1 Agonists ... site pain. --- ... #GLP1 #Agonists ... #Pharmacology #Dosing ... Diabetes #DM2 #Endocrinology
Pain Assessment and Management Initiative (PAMI) - Ketamine Dosing

#Management #Pain #Pharmacology #Ketamine #Analgesia #Subdissociative #ExcitedDelirium #Doses
Pain Assessment ... ) - Ketamine Dosing ... #Pharmacology # ... Ketamine #Analgesia ... #Table #PAMI
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
GLP-1 Receptor Agonists ... - Pharmacology ... Ozempic), or daily tablet ... #Pharmacology # ... DM2 #diabetes #endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
-1 Agonist Dosing ... drug to remain stable ... GLP1 agonists are ... semaglutide #Diabetes #Pharmacology ... #Endocrinology
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
4 Inhibitors - Pharmacology ... normally inactivates GLP ... receptor agonist ... Toxicities: • Joint pains ... DM2 #diabetes #endocrinology